← Back to Clinical Trials
Recruiting NCT07566975

NCT07566975 Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07566975
Status Recruiting
Phase
Sponsor Neuro-Ophthalmology of Texas
Condition Dry Eye
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2026-03-31
Primary Completion 2026-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Cyclosporine ophthalmic solution 0.1%

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2026-03-31 with a primary completion date of 2026-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye

Eligibility Criteria

Inclusion Criteria: * Age18 yr or older Diagnosis of neuro-ophthalmic condition Clinical diagnosis of dry eye disease OSDI score of 23 or greater at baseline Objective sign present Indicated for VEVYE prior to enrollment Ability and willingness to complete study visits and questionnaires Exclusion Criteria: * Patients with a corneal ulcer Use of another cyclosporine or lifitegrast product within 30 days of baseline Ocular surgery within 30 prior to baseline Active ocular infection or severe ocular surface condition unrelated to DED Contact lens wearers ( must be off contacts for 30 days and the duration of trial) Any condition that prevents compliance or informed consent Subjects with severe scarring / zero sensitivity

Contact & Investigator

Central Contact

Laura Perez

✉ lperez@neuroeye.com

📞 12817238593

Principal Investigator

Rosa A. Tang

PRINCIPAL INVESTIGATOR

Neuro Ophthalmology of TX

Frequently Asked Questions

Who can join the NCT07566975 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Dry Eye. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07566975 currently recruiting?

Yes, NCT07566975 is actively recruiting participants. Contact the research team at lperez@neuroeye.com for enrollment information.

Where is the NCT07566975 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT07566975 clinical trial?

NCT07566975 is sponsored by Neuro-Ophthalmology of Texas. The principal investigator is Rosa A. Tang at Neuro Ophthalmology of TX. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology